alone. Cytotoxicity was detectable in preparations from donors in all categories examined, including those from individuals without any known abnormality, so that differences between groups were quantitative rather than qualitative.
Leucocytes from 14 patients with ulcerative colitis showed significantly greater reactivity against cells cultured from malignant, normal and foetal colonic tissue than did those from the 22 healthy donors. Similarly, leucocytes from the 13 patients with colonic neoplasia displayed marked ability to kill cells, particularly those originating from the foetal gut. However, there was no evidence that the leucocytes from these patients were cytotoxic for colon cancer derived target cells. The leucocytotoxicity for the cells from malignant, normal and foetal colonic tissue in patients with other colonic disorders including Crohn's disease and spastic colon syndrome (7 patients each), and non-colonic tumours (20 patients The toxicity of the anti-tumour agent cis Platinum (II) diamminedichloride, (cis Pt (II), towards Chinese Hamster V79-379A cells was enhanced by post-treatment incubation in the presence of a non-toxic concentration of the purine analogue caffeine. Cis Pt (II) also induced chromosome aberrations in this cell line, and the frequency and severity of this damage were increased by caffeine. A time-course study of the appearance of chromosome aberrations suggested that these aberrations arise as a result of DNA synthesis on a damaged template. The ability of caffeine to enhance the toxic and chromosome-damaging effect of cis Pt (II) may be attributable to its ability to interfere with a post-replicative NDA repair mechanism, and molecular studies using alkaline sucrose gradient techniques have shown that DNA is made in smaller segments in cis Pt (II) treated cells in the presence of caffeine. Cytotoxic activity of cis-dischlorobis (cyclopentylamine) platinum II (DBCP) has been studied using CHO cells. The half-life of DBCP was determined as well as the dosesurvival relationship in medium containing Na+ and Cl-at two different concentrations.
CIS-DICHLOROBIS (CYCLOPENTY-
The data obtained are summarized in the Table. From experiments performed on synchronized CHO cells, it is concluded that DBCP is not a phase-specific drug at a dose level reducing survival to about 25%. Among early effects of DBCP treatment are inhibition of 3H-TdR incorporation into DNA and inhibition of cell division. Clone-size analysis performed for the first 5 days after treatment revealed the presence of nonlethal damage. DBCP was found to be dosemodifying for ionizing radiation (a factor of 12) when applied 1 h before or 1 h after irradiation. 
